Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News Sobi bets on late-stage gout asset with acquisition of Arthrosi Therapeutics Swedish Orphan Biovitrum is acquiring Arthrosi Therapeutics for $950 million to bolster its inflammation pipeline. Explore what this means for its growth trajectory. bySrinathDecember 14, 2025